Our molecular docking results showed that all three selected compounds (quercetin, beta-sitosterol, and kaempferol) had high affinities for the three core targets (AKT1, IL6, and IL1B), as their binding energies to proteins were < -5 kcal/mol (Table 1); this suggests that these compounds may play crucial roles in the treatment of DVT. The gene discussed is IL6; the disease is deep vein thrombosis.